GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: In vitro, kinetic, and in vivo characterization

Journal of Pharmacology and Experimental Therapeutics

Volumn 337, Issue 1, 2011, Pages 145-154

  Tralau Stewart, Cathy J ^b   Williamson, Richard A ^a   Nials, Anthony T ^a   Gascoigne, Michele ^a   Dawson, John ^a   Hart, Graham J ^a   Angell, Anthony D R ^a   Solanke, Yemisi E ^a   Lucas, Fiona S ^a   Wiseman, Joanne ^a   Ward, Peter ^a   Ranshaw, Lisa E ^a   Knowles, Richard G ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CILOMILAST; FLUTICASONE PROPIONATE; GSK 256066; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; PHOSPHODIESTERASE VI; ROFLUMILAST; SPLEEN EXONUCLEASE; TOFIMILAST; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LUNG DISEASE; MALE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PULMONARY NEUTROPHILIA; RAT;

ADMINISTRATION, INHALATION; AMINOQUINOLINES; ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKOCYTES, MONONUCLEAR; PHOSPHODIESTERASE 4 INHIBITORS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SULFONES;

EID: 79953022070     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.173690     Document Type: Article

References (35)

1. Barnette MS, Christensen SB, Essayan DM, Esser KM, Grous M, Huang S-K, Manning CD, Prabhakar U, Rush J, and Torphy TJ (1994) SB 207499, a potent and selective phosphodiesterase (PDE) IV inhibitor suppresses activities of several immune and inflammatory cells. Am J Resp Crit Care Med 149:A209.
2. Boswell-Smith V, Spina D, and Page CP (2006) Phosphodiesterase inhibitors. Br J Pharmacol 147:S252-S257. (Pubitemid 43077283)
3. Brown WM (2005) Cilomilast GlaxoSmithKline. Curr Opin Investig Drugs 6:545-558.
4. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, and Beume R (2001) In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 297:280-290.
5. Cha S (1976) Tight-binding inhibitors - III. A new approach for the determination of competition between tight-binding inhibitors and substrates-inhibition of adenosine deaminase by coformycin. Biochem Pharmacol 25:2695-2702.
6. Daguès N, Pawlowski V, Guigon G, Ledieu D, Sobry C, Hanton G, Freslon JL, and Chevalier S (2007) Altered gene expression in rat mesenteric tissue following in vivo exposure to a phosphodiesterase 4 inhibitor. Toxicol Appl Pharmacol 218:52-63. (Pubitemid 46026843)
7. Dastidar SG, Rajagopal D, and Ray A (2007) Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs 8:364-372. (Pubitemid 46700993)
8. Davis TG, Peterson JJ, Kou JP, Capper-Spudich EA, Ball D, Nials AT, Wiseman J, Solanke YE, Lucas FS, Williamson RA, et al. (2009) The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1- piperazinyl)methyl]- 1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H- pyrazolo[3,4-b]pyridin-4- amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity. J Pharmacol Exp Ther 330:922-931.
9. Dharmasena SP, Wimalasena DS, and Wimalasena K (2002) A slow-tight binding inhibitor of dopamine β-monooxygenase: a transition state analogue for the product release state. Biochemistry 41:12414-12420.
10. Duplantier AJ, Bachert EL, Cheng JB, Cohan VL, Jenkinson TH, Kraus KG, McKechney MW, Pillar JD, and Watson JW (2007) SAR of a series of 5-6 dihydro-(9H)-pyrazolo [3,4-c]-1,2,4-triazolo [4,3-α] pyradines as potent inhibitors of human eosinophil phosphodiesterase. J Med Chem 50:344-349.
11. Dyke HJ and Montana JG (1999) The therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 8:1301-1325. (Pubitemid 29417617)
12. Dyke HJ and Montana JG (2002) Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 11:1-13. (Pubitemid 34048615)
13. Evans KS, Coleman RA, Nials AT, and Vardey CJ (1995) The anti-inflammatory and behavioural effects of phosphodiesterase inhibitors in the conscious rat, in Proceedings Supplement: Proceedings of the British Pharmacological Society Meeting; 1995 Jul 12-14; Oxford, UK. Vol 116, pp 88, British Pharmacological Society, London, UK.
14. Giembycz MA (2001) Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 10:1361-1379.
15. Hatzelmann A and Schudt C (2001) Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297:267-279. (Pubitemid 32242587)
16. Hebenstreit GF, Fellerer K, Fichte K, Fischer G, Geyer N, Meya U, Sastre-y-Hernández M, Schöny W, Schratzer M, and Soukop W (1989) Rolipram in major depressive disorder: results of a double blind comparative study with imipramine. Pharmacopsychiatry 22:156-160. (Pubitemid 19176094)
17. Hirose R, Manabe H, Yanagawa K, Ohshima E, and Ichimura M (2008) Differential effects of PDE4 inhibitors on cortical neurons and T-lymphocytes. J Pharmacol Sci 106:310-317. (Pubitemid 351366352)
18. Horowski R and Sastre-y-Hernandez M (1985) Clinical effects of neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports. Curr Ther Res 38:23-29. (Pubitemid 15030877)
19. Houslay MD (2001) PDE4 cAMP-specific phosphodiesterases. Prog Nucleic Acid Res Mol Biol 69:249-315.
20. Knowles RG, Tralau-Stewart CJ, Dawson J, Hart GJ, Angell ADR, Solanke YE, Lucas FS, Wiseman J, Ward P and Williamson RA (2009) In vitro characterisation of GSK256066, an exceptionally high affinity and selective inhibitor of PDE4 suitable for administration by inhalation; at the American Thoracic Society Meeting; 2009 May 15-20; San Diego, CA; Vol 179, pp A4581, American Thoracic Society, New York, NY.
21. Kuss H, Hoefgen N, Johanssen S, Kronbach T, and Rundfeldt C (2003) In vivo efficacy in airway disease models of N-(3,5-dichloro-pyrid-4-yl)-[1-(4- flurobenzyl)- 5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration. J Pharmacol Exp Ther 307:373-385.
22. m, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. Cloning and expression of cDNA, biochemical characterization of recombinant protein, and tissue distribution of mRNA. J Biol Chem 268:6470-6476.
23. Morrison JF (1969) Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim Biophys Acta 185:269-286.
24. Morrison JF and Walsh CT (1988) The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 61:201-301.
25. Nials AT, Tralau-Stewart CJ, Gascoigne MH, Ball DI, Ranshaw L, and Knowles RG (2010) GSK256066, a highly potent long-acting inhaled inhibitor of phosphodiesterase 4 with an improved therapeutic index. J Pharmacol Exp Ther doi;10.1124/jpet.110.173641.
26. Pauwels RA, Kips JC, Peleman RA, and Van Der Straeten ME (1990) The effect of endotoxin inhalation on airway responsiveness and cellular influx in rats. Am Rev Respir Dis 141:540-545. (Pubitemid 20109134)
27. Raeburn D, Underwood SL, Lewis SA, Woodman VR, Battram CH, Tomkinson A, Sharma S, Jordan R, Souness JE, and Webber SE (1994) Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Br J Pharmacol 113:1423-1431. (Pubitemid 24364430)
28. Torphy TJ, Barnette MS, Underwood DC, Griswold DE, Christensen SB, Murdoch RD, Nieman RB, and Compton CH (1999) Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 12:131-135. (Pubitemid 29366508)
29. Torphy TJ, Stadel JM, Burman M, Cieslinski LB, McLaughlin MM, White JR, and Livi GP (1992) Coexpression of human cAMP-specific phosphodioesterase activity and high affinity rolipram binding in yeast. J Biol Chem 267:1798-1804.
30. Torphy TJ and Undem BJ (1991) Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 46:512-523.
31. Torphy TJ, Undem BJ, Cieslinski LB, Luttmann MA, Reeves ML, and Hay DW (1993) Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle. J Pharmacol Exp Ther 265:1213-1223. (Pubitemid 23321022)
32. Underwood DC, Bochnowicz S, Osborn RR, Kotzer CJ, Luttmann MA, Hay DW, Gorycki PD, Christensen SB, and Torphy TJ (1998) Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig. J Pharmacol Exp Ther 287:988-995. (Pubitemid 29131612)
33. Underwood DC, Osborn RR, Novak LB, Matthews JK, Newsholme SJ, Undem BJ, Hand JM, and Torphy TJ (1993) Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram. J Pharmacol Exp Ther 266:306-313. (Pubitemid 23315663)
34. Williams JW, Morrison JF, and Duggleby RG (1979) Methotrexate, a high-affinity pseudosubstrate of dihydrofolate reductase. Biochemistry 18:2567-2573. (Pubitemid 9203282)
35. Woodrow MD, Ballantine SP, Barker MD, Clarke BJ, Dawson J, Dean TW, Delves CJ, Evans B, Gough SL, Guntrip SB, et al. (2009) Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration. Bioorg Med Chem lett 19:5261-5265.